chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Day 1-Day 3:Sore arm, swollen, hot to the touch, red irritation at injection site, tiredness, trouble concentrating.  Day 4-6: arm swollen more, hot to touch, irritation at Injection site, mobility of arm impaired.  Day 5: massaged arm to get swelling to go down. Day 6: woke up with massive headache and swelling went down. Day 7: broke out in hives that turned into blisters, taken to ER and given prednisone and antihistamine. Day 8-10: arm is black and blue bruised at injection site, small lump at site, continuous rotating hives and blisters with Prednisone 160mg and antihistamine and creams.
DX of COVID-19, Patient is a 77yo female, hx of colon cancer presenting with 4 days of fatigue, cough, and headache. Initially started as cough and fatigue. Later progressed to severe headache. No hx of frequent headaches. Additional symptoms: abdominal pain, dizziness and nausea.  Given additional migraine medications with resolution of her headache. Patient currently ranges from 91-95% on RA. Discussed with family. Patient would prefer to go home and return if symptoms worsen. Provided ambulatory pulse ox. Told to follow up with PCP in 2-3 days.
shingles; Information has been received from a lawyer regarding a case in litigation and refers to a female patient (pt) of an unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On 01-MAR-2010, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, dose number, route, anatomical site of vaccination, lot number and expiration date were not provided) as prescribed and/or administered by a pharmacist for the long-term prevention of shingles and/or zoster-related conditions. On an unknown date (reported as subsequent to pt's zoster vaccine live (ZOSTAVAX) inoculation), the pt was treated by a healthcare provider for shingles (herpes zoster). On an unknown date, she was admitted to the hospital due to the event. As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, she had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. At the time of this report, the outcome of herpes zoster was unknown. The lawyer considered the event to be related to zoster vaccine live (ZOSTAVAX).
Patient seen 3/14/07, with 10 cm x 7 cm erythematous/warm site on L arm. Pt seen 3/12/07 to follow up L ear cellulitis doing well treated with Keflex 3/5/07.
mom said several wk p/vax pt stopped walking, had some redness & swelling right p/inj;
Facial numbness - entire face.  Started about 30 minutes after injection.  It is better now (approximately 5 hours later) but it is still present. A bit hot feeling now.
lt deltoid became red, sore, swollen, hot to touch was dx w/cellulitis on 6JAN93; tx Dicloxucillin
Pt was nauseated at time of vaccination from increased nervousness and anxious. He fell over after the shot and hit head on the table and had a red mark on his the right side of his forehead. While on the floor he was shaking and mumbling something. He was out for 10-45 seconds. Pt didn?t realize what had happened. Paramedics were called in to evaluate him.
Blood clot; Pain; This spontaneous case was reported by a consumer and describes the occurrence of THROMBOSIS (Blood clot) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced THROMBOSIS (Blood clot) (seriousness criterion medically significant) and PAIN (Pain). At the time of the report, THROMBOSIS (Blood clot) and PAIN (Pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Company comment: Limited information regarding the events has been provided at this time and a causal relationship cannot be excluded
Joint pain, knees & hands,fatigue, HA - at time of vaccine 2nd dose 1999; Antibiotics, Plaqueril and alternative medicine
physucuan reported that three out of eight pts who received this product, from this lot, developed severe local (deltoid) rxns. Rxn were redness, swelling, & pain of the deltoid.
Every bone in my body hurt, I was unable to get out of bed until 4:00pm because of a overwhelming not well feeling  (a little  Nauseous and dizzy but not to the point I was throwing up I also had a low-grade fever 99.7 and could not get warm.  Over the past 2 hours I am feeling a little better where I can walk short distances and type in my phone  I did not go to the doctor or hospital
Upper neck by base of skull severe pain. Like someone smacked me with hammer .; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 03Jul2021 10:00 (Lot number: EW0196) at the age of 51 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "sinus infection" (unspecified if ongoing); "known allergies: Egg whites" (unspecified if ongoing), notes: known allergies: Egg whites. Concomitant medication(s) included: PREDNISONE; AMOXCLAV [AMOXICILLIN;CLAVULANIC ACID]; COMBIVENT; SYMBICORT. The following information was reported: NECK PAIN (non-serious) with onset 04Jul2021 04:00, outcome "not recovered", described as "Upper neck by base of skull severe pain. Like someone smacked me with hammer .". Therapeutic measures were not taken as a result of neck pain.  Additional information: The patient reported no other vaccine in four week. Patient did not reported any COVID prior vaccination and not reported COVID tested post vaccination.  No follow-up attempts are possible. No further information is expected.
Brief episode (a couple minutes) of extreme heart rate with no stress or unusual activity leading up to it. Approximately 230 BPM (checked with a metronome). Could not be managed by any sort of breath control. Sat down when I could and eventually it just stopped and went back to normal. I have no history of heart problems and did not have unusual side effects after the previous two shots.
This case was reported by a pharmacist and described the occurrence of red rash injection site in a subject of unspecified age and gender who was vaccinated with FLUARIX, (GlaxoSmithKline).  In October 2008, the subject received a dose of FLUARIX (.5 ml, unknown).  In October 2008, at an unspecified time after vaccination with FLUARIX, the subject experienced red rash injection site and pharmaceutical product complaint.  The pharmacist received a call from a nurse at a nursing home facility that reported that 80 out of 100 subjects developed a "grapefruit size bright red" rash at the injection site.  At the time of reporting the outcome of the events were unspecified.  For the other 79 linked subjects please see cases : A0756483A - A0756540A, A0756542A - A0756562A.  The CRC provided lot number AFLUA3208A to QA regarding this product complaint, while the report received in CMG Safety stated AFLUA3508A.  With a possibility of a coding mistake to batch AFLUA320AA and on the basis that there are 80 cases out of 100, it was decided to ask for a Quality investigation (including cold chain) of all three batches (correct numbers : AFLUA350BA, AFLUA320BA and AFLUA320AA).  On 16 January 2009, QA results were received for batches reviewed of (AFLUA320AA and AFLUA320BA) : AFLUCA320, AFLUA320A, and AFLUA320B.  The report indicated that no deviation that could be linked to the complaint and no cold chain deviation was recorded on the batches AFLUA320AA and AFLUA320BA.  On 26 March 2009, QA results were received for batches reviewed (AFLUA350BA) : AFLUCA350 and AFLUA350B.  The report indicated that no deviation that could be linked to the complaint and no cold chain deviation was recorded on the batch AFLUA350BA.
Patient presented to mc for progressive SOB/DOE starting gradually around the time of 2nd dose and progressing - CTA showed b/l PEs and admitted to hospital & anticoagulated. No clear source. Had concerning r:Q scan 1 yr ago but CTA showed one pneumonia then
Chills, aches. Arm pain, large red rock hard welt at injection site  Received at same time as flu vaccine in same arm (left)
Administerd vaccine that was not stored in recommended temprature; A report was received from a health care professional concerning a 29-year old patient participating in the mRNA-1273 Emergency Use Program who was administered vaccine that was not stored in recommended temperature.  The patient's medical history was not provided. No relevant concomitant medications were reported.   The patient received their first of two planned doses of mRNA-1273 (Lot 011J20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection on 21 Dec 2020. On the same day, the nurse noticed administered vaccine was not stored in recommended temperature. Temperature reading of -21.6 and -20.9 ranges were in Fahrenheit instead of Celsius as the freezer reading was set to Fahrenheit. The nurse called to inquire whether the vaccine is usable. No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not reported.   The outcome of the event, administered vaccine that was not stored in recommended temperature, was unknown.   The reporter did not provide an assessment for the event of administered vaccine that was not stored in recommended temperature.; Reporter's Comments: This case concerns a 29-year-old patient who received their first of two planned doses of mRNA-1273 (Lot 011J20A), reporting Product storage error without any associated adverse events.
Guillain-Barre - case is considered to be very mild and he can continue his workup in the outpatient setting.
Dose administered after manufacturer date of expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048L21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jul-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that the patient received first booster dose of Moderna vaccine on 11-Jul-2022 from a vial containing 3 doses.  It was reported that the vial was initially stored in the refrigerator on 11-Jul-2022. The vial was thawed for the first time on 11-Jul-2022.  The vial did not undergo any temperature excursions. The reporter asked what action needs to be taken further in regards to the expired vaccine administration.  No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2022-608564, US-MODERNATX, INC.-MOD-2022-608562 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-608564:3rd Patient (same reporter) US-MODERNATX, INC.-MOD-2022-608562:2nd Patient (same reporter)
Initial unsolicited report received from a Nurse on 15 October 2015. This case involves a female patient (age not reported) who was vaccinated with a dose of INFLUENZA VACCINE (Flu shot) (batch number, route and site of administration were not reported) on an unspecified date. The patient's medical history and concomitant medications were not reported. On an unspecified date, following the vaccination, the patient had experienced a reaction(unspecified). Laboratory data and corrective treatment were not reported. The outcome of the event was not reported. List of documents held by sender: none.
This spontaneous report was received from a pharmacist refers to a 64 year old female patient with penicillin allergy. The patient had a reported history of rash after taking penicillin in the past. The patient's medical history included right kidney damage. On 11-SEP-2013, the patient was vaccinated with a dose of ZOSTAVAX (lot # J003359, expiry: 21-JUN-2014) subcutaneously in the left upper arm. On 11-SEP-2013 in the evening, the patient experienced tingling down her left arm to the fingers. The patient also developed a "50 cent sized" area of redness, swelling, soreness, and warmth at the injection site. On 13-SEP-2013, the patient reported an increase in the tingling sensation. Patient sought medical attention-called the pharmacist. No treatment was given. No laboratory tests were performed. Today, 16-SEP-2013, the patient reported the affected area was still sore but the tingling had improved. The outcome of the events were reported as recovering. Additional information has been requested.
This spontaneous report as received from a pharmacist refers to a 52 year old female patient. The patient's medical history, past drug history, or concomitant medications were unknown. On 15-AUG-2014 the patient was vaccinated with a dose of expired PNEUMOVAX23 (lot # J009827, exp. date: 10-AUG-2014, 0.5 ml, injection, site and route of administration not reported). The patient did not have any relevant laboratory data or tests. As of 15-AUG-2014, it was unknown if the patient would continue to receive PNEUMOVAX23, and the outcome of receiving an expired vaccine was reported as unknown. Additional information has been requested.
Blood pressure kept steady going up, chest pain, breathing troubles, migraine, vomitting, hot and cold body temp, and body aches, went to ER around 1:30 PM the same day. Exhaustion. Diagnoed with high blood pressure and  myocardiovascular congestive. Still dealing with the issues, Was in ER for 14 hours then sent home.
Experiencing chest/lung pain. Indicates injection site soreness.; Experiencing chest/lung pain. Indicates injection site soreness.; Experiencing chest/lung pain. Indicates injection site soreness.; This is a spontaneous report from a contactable health care professional .   A 49 year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 12Feb2021 (Batch/Lot number was not reported) at 11:00 as a single dose for covid-19 immunisation  .  Medical history and concomitant medications were not reported.  The patient received  the vaccine and was experiencing chest/lung pain. Indicates injection site soreness. Questions about Tylenol/Advil. The outcome of the events was not reported.  Information on the lot/batch number has been requested.
Pt reports onset of fatigue on 9/25/15 PM that progressed over the weekend. Saw MD on Monday 9/28/15 and was diagnosed with bronchitis and pneumonia. Was prescribed Z-PAK, nebulizer and steroid.
Longer than recommended interval; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 6th December 2018).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Longer than recommended interval). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 06-NOV-2023 The pharmacist contacted GSK via phone inquiring about Shingrix and what information was available about the administration of Shingrix after the recommended interval.  They gave partial information about the event, patient and vaccine. The vaccine administration facility was the same as primary reporter. Till the time of reporting, the patient did not received 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter consented to follow up.
I have continuous pain in my right heel and it is the same type of paid I had when I took the levaquin.  Have tried heel pads and acupuncture but nothing alleviates the pain.  No one has been able to determine the cause of the pain.  Last week I was thinking about the medicines I had been taking before and after the covid shot and the only new medicine was the shot.
fever & chills;rash w/itching;used DPh & lanocaine, had welts disappeared & then came back;to MD dx hives taking Clariton using Aveeno lotion, DPH gel;
nausea, vomiting, muscle pain, joint pain, chills, decrease appetite. start date 04/19/22 was told by my primary cares office to call where i got the vaccine to see what i need to do. I called county health department to see what they recommend. Health department gave me this website address to side effects. I haven't been seen by my provider since they cancel my appointment.
1 hour after vax I experienced a feeling of electric shock in a straight line through chest, both arms. lasted maybe a minute. pain scale 8/10. went away as soon as it came. occured 3 times.  Next day occured once.  Regular symptoms of fever, muscle soreness etc went away after two days.  next day nothing much.  next day chest pain center. 2/3 out of 10 pain scale  next day i leave work due to chest pain. job is physically demanding.  that thursday i go to medical center ER for chest pain 6/10 immediately following sex at maybe 11pm or midnight.  next few days till now:  chest pain extends to neck. not consistent locations. center chest/left of chest/neck. exertion sometimes triggers pain. sometimes not.
After having the shot, hedeveloped left arm pain and did develop some lymphadenopathy in his left axillary region.  He was dealing with nausea and dizziness, and the following day, he went to work, although he was feeling a bit ill.  While at work, he was found to have a fever, so he was sent home.  He has been having hot and cold flashes since then.  He has had a poor appetite.  He has had a dry mouth and trouble sleeping.  One day prior to admission, he then developed a chest pain that became constant and persisted, so he came into the emergency department on 05/19/2021 for further care. He has developed myocarditis after receiving the first of his Moderna Coronavirus Disease 19 vaccines.
1st dose December 23, 2020.  Arm pain, swelling, raised red 3 inch bump developed within 12 hours.  Subsided, and reoccurred about 10 days post vaccine.  10-14 days post vaccine I developed New onset forefoot weakness (foot drop) Right, new onset trigger finger Right middle finger, new onset bladder spasms with immediacy and incontinence - not bladder volume dependent, resurgence of body aches, new bilateral knee pain requiring two arm support for sit to stand,  Mental status changes including anxiety, paranoia, mania and depression (personality change!), motion induced nausea and dizziness, visual changes (blurry vision), New intensification of nocturnal muscles spasms - bilateral and progressive and intermittent headache up the Right neck to crown, New onset (01/14/21 - present) burning rubber scent when some food being cooked.  The muscle and joint pain were present with February illness, subsided by April, and came back with a vengeance within two weeks of the 1st injection.  I also lost three teeth (fracture vertically while flossing), thinned hair, and had intermittent dizziness during the initial illness in February.   February Initial loss of taste/smell included metallic taste with artificial flavors, rotten garbage - random, and ?iron taste with meats.  I can now taste some fruits but only get bitterness with other fruits and vegetables.  I had one sided facial paralysis after tooth extractions in September - resolved in 1 week.  I required dental implants to replace the fractured teeth.  I am a vaccinator, and have been administering our vaccines and swabbing for Covid testing since we reopened elective procedures.  I strongly encourage our staff to get the vaccines - and I am the one who gets the reaction.  The constellation of symptoms, temporal proximity to the vaccine with no intervening illness or injury, and commonality of some symptoms with my February illness have prompted further testing and evaluation for central nervous system insult.
ED to Hosp-Admission Discharged  5/19/2021 - 5/24/2021 (5 days)   Last attending ? Treatment team Acute respiratory failure with hypoxia  DETAILS OF HOSPITAL STAY   Presenting Problem/History of Present Illness/Reason for Admission From admission  " Patient is a 88 y.o. female who presents to the hospital today withincreasing weakness, falls over the last few days.  She has not been eating or drinking well.  It appears she recently started a sulfonylurea.  EMS arrived blood sugar 58 and upon arrival to the ER blood sugar was 35 and she was lethargic.  Given orange juice and a dextrose bolus with improvement of her blood sugar.  Room air sat was 88% on room air however she only feels short of breath but she did not wear oxygen at home.  Family member has Covid but she does not endorse any contact with them. In ED she was found to be positive for COVID19, with AKI and SIRS and internal medicine was asked to admit the patient."   Hospital Course Patient mandatory medical surgical floor.  She was found to have acute hypoxic respiratory failure due to COVID-19 pneumonia.  She was found to be 88% on room air and was requiring 3 L of nasal cannula oxygen fourth her first 3 days of admission.  She received treatment for her viral infection with IV remdesivir as well as IV dexamethasone to complete 5 days.  She also was treated with azithromycin and ceftriaxone.  However this was later stopped as her procalcitonin level was not negative.  Because her urine showed pyuria she was continued on IV ceftriaxone.  However her culture only grew 30,000 colonies of E. coli in 50,000 colonies of Streptococcus and get gnosis.  She was fully treated for a UTI.   She was successfully weaned off of oxygen onto room air on May 23 and remained stable overnight into the day of discharge.  She was seen by physical therapy due to her history of ambulatory dysfunction and rehab was recommended for her.  However the patient refused she felt that she had enough family support and assistance at home to return home.  Home services were also recommended including home physical therapy which the patient also declined.   She will need to follow-up with her family doctor in the next 7 days.  A referral for pulmonology was also made on the day of discharge for 1-2 days.
12/16/2021 - Came to ER with weakness/abdominal pain. Temp 101.8 with rest of vitals WNL. Admitted for upper GI bleed and tested positive for COVID. Chest Xray reveals Covid pneumonia. Decadron x1, Zosyn x1, Cefepime x1, and Remdesivir ordered. On room air and denies SOB.  12/17 - Continuing treatment with Ceftriaxone, Doxycycline, and Remdisivir. Afebrile.  12/20 - Covid treatment medications continued. PRBC issued for anemia treatment.  12/21 - Remdesivir course complete. Discharged to home for completion of antibiotic/steroid. Anemia chronic - so patient wishes to follow up with PCP.